What one share of Amylyx Pharmaceuticals holds
Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases.
Amylyx Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.43 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.19 |
| Cash and investments | $2.25 |
| Book value | $2.15 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.04 | −$13.35 | $0.05 | −$11.41 | — | −$21.53 |
| 2022 | $0.38 | −$3.39 | $0.04 | −$3.12 | — | $5.12 |
| 2023 | $5.44 | $0.70 | $0.02 | $0.15 | — | $6.40 |
| 2024 | $1.28 | −$4.43 | $0.00 | −$2.46 | — | $2.40 |
| 2025 | $0.00 | −$1.53 | $0.00 | −$1.31 | — | $2.78 |
Common questions about Amylyx Pharmaceuticals
How much does one share of Amylyx Pharmaceuticals earn?
Over the last 12 months, Amylyx Pharmaceuticals lost $1.43 for each share.
Does Amylyx Pharmaceuticals pay a dividend?
Amylyx Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Amylyx Pharmaceuticals’s book value per share?
Amylyx Pharmaceuticals’s book value is $2.15 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Amylyx Pharmaceuticals have?
Each share of Amylyx Pharmaceuticals has $2.25 of cash and investments, as of June 30, 2026.
What is Amylyx Pharmaceuticals’s free cash flow per share?
−$1.19 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Amylyx Pharmaceuticals bought back shares?
Amylyx Pharmaceuticals’s share count rose about 1336% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.